Improving Treatment Outcomes for Prescription Opioid Dependence
Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Overall, this proposal seeks to improve treatment strategies for the significant public
health problem of prescription opioid dependence by determining whether gabapentin, a
non-narcotic pharmaceutical agent with minimal abuse potential and preliminary efficacy, will
be effective in ameliorating withdrawal symptoms, craving and illicit drug use in
prescription opioid dependent participants undergoing a 10-day detoxification from
buprenorphine. In addition, the acceptability and feasibility of transitioning to depot
naltrexone therapy will also be determined. If successful, this study would provide data to
support further development of gabapentin as a pharmacological tool for improved outcomes
during opioid detoxification as well as an integrated outpatient approach for treating
prescription opioid dependence.